We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Coating for Vascular Grafts Dissolves Blood Clots

By HospiMedica International staff writers
Posted on 24 Aug 2015
A novel thrombolytic coating for vascular grafts could obviate the need for continuous use of anticoagulants, according to a new study. More...


Researchers at ITMO University (St. Petersburg, Russia) and Petrozavodsk State University (Russia) have developed a new family of injectable composites for treating thrombolysism composed of urokinase plasminogen activator entrapped within alumina. The thrombolytic coating is a sol-gel made of nanocrystalline oxides, and can thus lock the necessary thrombolytic enzymes inside the polymer vascular graft, making the productive lifespan of the graft virtually limitless.

The nanoarchitecture of the sol-gel thrombolytic coating is also bio-inert, ensuring near perfect stability. According to the researchers, the alumina, which serves as the urokinase plasminogen activator carrier, helps to prolong its activity in vivo and reduce the total administered dose of anticoagulant drugs necessary following a stent graft procedure, and hence the eventual side effects, such as the danger of hemorrhagic stroke. The study was published on August 13, 2015, in the Journal of Medicinal Chemistry.

“Modern vascular grafts are medicated and they emit the drug into the bloodstream; however, the concentration of the medication in the graft decreases with time and then clots may reappear. This coating provides unhampered bloodstream preventing thrombosis,” said lead author Yulia Chapurina, MSc, of the ITMO laboratory of solution chemistry of advanced materials and technologies. “The new technology is based on drug entrapping. It means that the protective coating holds it inside the vascular graft.”

The sol-gel process is a method for producing solid materials from small molecules, and is used for the fabrication of metal oxides, especially the oxides of silicon and titanium. In the procedure, the 'sol' (solution) gradually evolves towards the formation of a gel-like diphasic system containing both a liquid phase and solid phase whose morphologies range from discrete particles to continuous polymer networks. The unique properties of the sol-gel provide the possibility of their use for a variety of medical applications.

Related Links:

ITMO University
Petrozavodsk State University



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Absorbable Monofilament Mesh
Phasix Mesh
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.